H.C. Wainwright raised the firm’s price target on Cytokinetics to $120 from $90 and keeps a Buy rating on the shares. The firm cites the re-inclusion of omecamtiv mecarbil in the valuation for the target increase. If aficamten is approved, data support it surpassing Camzyos, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics presents additional data from SEQUOIA-HCM trial
- Cytokinetics presents additional data from SEQUOIA-HCM
- Edgewise Therapeutics price target raised to $42 from $32 at Leerink
- Cytokinetics announces data from Phase 1 study of CK-4021586
- Cytokinetics price target raised to $71 from $65 at JPMorgan